Joined Atuka in 2011. He has a Ph.D. in Neuroscience, from the University of Manchester, UK (1997) and has more than 15 years’ experience in Parkinson’s disease research. Previously, he held the position of Chief Operating Officer at a CRO where he lead translational research that has supported the assessment of efficacy of more than 30 drug candidates in rodent and non-human primate models of PD, 7 of which advanced to clinical studies. These and other studies are detailed in 31 peer-reviewed publications.
Description & References:
Product Spec:
CAS No.:
Molecular Structure:
Jonathan founded Atuka in 2003 and was its first CEO. He has a Ph.D. in Neuroscience, from the University of Manchester, UK (1991) and has more than 25 years’ experience in Parkinson’s disease research managing teams that have identified and validated many drug targets for PD. He has lead translational research that has supported the assessment of efficacy of more than 70 drug candidates in non-human primate models of PD and the advancement of 16 drug candidates to clinical studies. These and other studies are detailed in over 200 peer-reviewed publications.
In addition to his role in Atuka, Dr Brotchie enjoys a reputation for excellence as an academic researcher, leading research programs at University Health Network (2002-present) and University of Manchester (UK, 1991-2002).
Description & References:
Product Spec:
CAS No.:
Molecular Structure: